L3VLUP
ProSign in

SRRK · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SRRKGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SRRK
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterSRRKGILD
Q3 20202 holders, $2.5m25 holders, $14.2bn
Q4 20202 holders, $9.4m27 holders, $13.4bn
Q1 20211 holders, $7.0m24 holders, $14.5bn
Q2 20211 holders, $3.9m18 holders, $14.9bn
Q3 20211 holders, $4.5m20 holders, $16.4bn
Q4 2021none listed holders, n.a.20 holders, $16.8bn
Q1 2022none listed holders, n.a.28 holders, $13.2bn
Q2 20222 holders, $3.9m26 holders, $13.6bn
Q3 20221 holders, $508k24 holders, $13.3bn
Q4 20221 holders, $277k32 holders, $21.1bn
Q1 2023none listed holders, n.a.27 holders, $21.8bn
Q2 20232 holders, $3.8m24 holders, $20.7bn
Q3 20232 holders, $4.1m24 holders, $20.0bn
Q4 20233 holders, $195m22 holders, $21.5bn
Q1 20242 holders, $165m30 holders, $20.3bn
Q2 20241 holders, $5.9m28 holders, $18.5bn
Q3 20241 holders, $5.7m29 holders, $24.2bn
Q4 20248 holders, $1.2bn28 holders, $25.9bn
Q1 20258 holders, $933m33 holders, $32.0bn
Q2 20259 holders, $1.1bn27 holders, $30.9bn
Q3 202511 holders, $1.3bn23 holders, $29.4bn
Q4 202510 holders, $1.5bn25 holders, $34.3bn
Q1 202610 holders, $1.9bn25 holders, $38.5bn
Q2 20269 holders, $2.2bn26 holders, $34.2bn
SRRK

Scholar Rock HLDG Corp

Holders
9
Reported value
$1.1bn
Buyers
5
Sellers
2

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
27
Reported value
$30.9bn
Buyers
18
Sellers
10

Breadth +8 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2025

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SRRK (1)

Farallon Capital Management LLC

Only GILD (19)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Holocene Advisors LP, Invesco Ltd, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →